

**New Strategy for Circular RNA Preparation
: Circularization by Trans-Splicing Reaction**




FIG. 1A




FIG. 1B

New Strategy for Circular RNA Preparation : Circularization by Self-Targeting & Splicing (STS) Reaction




FIG. 2A




FIG. 2B




FIG. 2C

T7 Promoter

Antisense 150

GGGATTCGAACATCGATTAAATACGACTCACTATAGGGGCATCGATTGAATTGTCACGAATTCGGCGGCCAGCATGGAGAAATGCCATGGCTCAGCCAGGTAGTactgtgggtactcgaagTg

gctgctaccacaccgtcgattggagaaggggcacgtagaagttaggccctctgtgccattcatgctgtggccctgtggtgacctgaattTCgactccGcccaaAAAAAGTTATCAGGCATGCACCTGGTAGCTAGTCT

P1-P10 IGS

Trans-Splicing Ribozyme

Trans-Splicing Ribozyme

TTAAACCAATAGATTGCATCGGTTTAAAGGCAAGACCGTCAAATTGCGGAAAGGGGTCAACAGCCGTTCAGTACCAAGTCTCAGGGGAAACTTTGAGATGGCCTTGCAAAGGGTATG

GTAATAAGCTGACGGACAATGTTCTTAACCAACGCAGCCAAGTCTTAAGTCAACAGATCTTCTGTTGATATGGATGCGATTACAGACTAAATGTCGGTCGGGGAAGATGTAATCTTCTCAT

AAGATATAGTCGGACCTCTCCTTAATGGGAGCTAGCGGATGAAGTGAIGCAACACTGGAGCCGCTGGAACTAATTTGTATGCGAAAGTATATTGATTAGTTTTGGAGTACTCGcgagtagcg

CTTAAGAAAAAAGagggccggaaccTggccctgtctttgacgagcattcttaggggtctttccctctgcacaaagggaatcaaggTctgtgaatgtcgtgaaggagcagttctcttgaagcttcttgaagacaaaca

EMCV IRES

cgctgtagcgaccccttgaggcagcggaacccccacctggcgacaggtgctctgcggccaaaagccacgtgtataagatacacctgcaaaggcggcacaaccccgccacgcttgagttggaagagtcacaaatgg

ctctcctaagcgattcaacaaggggctgaaggatgcccgaaaggatccccattgatgggatctgatctgggacctcggtgcacatgttttagtcagggttaaaaaaacgtctagccccccgaaccacggggaacgtgggttttc

ctttgaaaacacgataagGcttgccacaaccCTTAAGaccggtAtgggagtc aaagttctgtttgccctgatactgcctgtggccgagggccaagccaccgagaaacaacgaagaacttcacatctgtggcgtgtggccagcaacttgg

Gene of interest (GOI, Gaussia Luciferase)

cgaccacggatctgatgtgaccgcgggaagttgccggccaagaagtccgctggagggtctcaagagatgnaagcattgcccgaaagctggctgaccacagggggtgtgtgtgtgttcccatactaagtgcacggccccaat

gaagaagtcatccaggacgctgcacacctacgaaggcgataaagagtcgcgcacagggcgcataggcgaggcgatcgcacattcctgggttcaggacttggagcccatggagccatggacagttcgcacaggtcgcgactctgt

gtgtggactgcacaaactggctgcctcaagggttgccaacgtgcagtglttctgacctgctcaagaagtggtcgccgcaacgtgtcgacctttgccagcaagatccaggggccagggttgacaagatcaaggggccgggtggtgactaaAA

Target Site

Antisense Binding Sequence

AAAAAAAaccggtTGGGTGGGAgcagccacgggtcagccacaaggccacagccatgaatggcacagaaggccctacttctacgtgcccttctccaatgcaggggtgtgtacgcagccActtcgagtaccacagTACTAC

CTGGCTGAGCCATGGCAGTTCTCCATGCTGGCCGCCAAGCTTGCCCTGAGCAGCGCTGCTCGAGAGATCT

FIG. 2D





FIG. 3



M: GenRuler 50 bp DNA Ladder (Thermo Scientific, SM0373)
1: EMCV-IRES-Gluc1-antisense IVT RNA Control + STS
2: EMCV-IRES-Gluc1-antisense IVT RNA Control + STS & RNase R
3: RZ004-EMCV-IRES-Gluc1-antisense IVT RNA: Direct STS
4: RZ004-EMCV-IRES-Gluc1-antisense IVT RNA: Direct STS & RNase R
5: NTC

FIG. 4A

G. Luci 3' end ↓ **IRES 5' end**





FIG. 4B



M1: 100 bp Plus DNA Ladder (Bioneer, D-1035)
M2: RiboRuler Low Range RNA Ladder (ThermoScientific, SM1831)
1: Circular RNA candidate 1 elu
2: Circular RNA candidate 1 elu (2.5 mM MgCl₂, 65°C 30 min)
3: Circular RNA candidate 1 elu (5 mM MgCl₂, 65°C 30 min)
4: Circular RNA candidate 2 elu
5: Circular RNA candidate 2 elu (2.5 mM MgCl₂, 65°C 30 min)
6: Circular RNA candidate 2 elu (5 mM MgCl₂, 65°C 30 min)
 100 ng RNA for the reaction/well

FIG. 5




FIG. 6A

Report gene expression




FIG. 6B

Splicing product RT-PCR




FIG. 6C




FIG. 6D

Analysis condition

- ✓ HPLC system: Agilent 1290 Infinity II Bio UHPLC
- ✓ Analytical column: Agilent PLRP-S 4000A 8um, 2.1 x 50mm
- ✓ Injection volume: 2 μ L (Prep 10 – 20uL)
- ✓ Flow rate: 0.5 mL/min
- ✓ Column oven temperature: 60 °C
- ✓ Detector: UV 260nm
- ✓ Mobile phase A: 100mM Hexylamine acetate pH7.0
- ✓ Mobile phase B: 100mM Hexylamine acetate in acetonitrile
- ✓ Gradient

- Fraction collection

Time(min)	%A	%B
0	70	30
2	70	30
15	45	55
16	10	90
17	10	90
17.1	70	30
20	70	30

- Analytical

Time(min)	%A	%B
0	80	20
2	80	20
50	40	60
51	10	90
53	10	90
53.1	80	20
56	80	20

- ✓ Collected from 96-well plate (PP, 250 uL) by increasing 2 position/6port valve position at interval of 0.1 minutes in range of fraction collection 9 minutes-12 minutes

FIG. 7A

2) KHL 1 IVT crude sample (Spin-column purification)




FIG. 7B

3) KHL 2 RNase R-treated IVT sample (Spin-column purification)




FIG. 7C





FIG. 8A



M1: 100 bp Plus DNA Ladder (Bioneer, D-1035)
M2: RiboRuler Low Range RNA Ladder (ThermoScientific, SM1831)
1: RZ004-EMCV-IRES-Gluc1-antisense IVT RNA: Fraction 7
2: RZ004-EMCV-IRES-Gluc1-antisense IVT RNA: Fraction 10
3: RZ004-EMCV-IRES-Gluc1-antisense IVT RNA: Fraction 11
4: RZ004-EMCV-IRES-Gluc1-antisense IVT RNA: Fraction 12
5: RZ004-EMCV-IRES-Gluc1-antisense IVT RNA: Fraction 13
 200 ng/well

FIG. 8B




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13

Target Site




FIG. 15




FIG. 16A




FIG. 16B





FIG. 17



M1: 100 bp Plus DNA Ladder (Bioneer, D-1035)
M2: RiboRuler Low Range RNA Ladder (ThermoScientific, SM1831)
1: RZ004-EMCV-IRES-Gluc1-AS150 (P1, P10, AS150) IVT RNA
2: RZ004-EMCV-IRES-Gluc1 (P1, No AS) IVT RNA
3: RZ001-EMCV-IRES-Gluc1 (P1, No AS) IVT RNA
4: RZ003-EMCV-IRES-Gluc1 (P1, No AS) IVT RNA
5: GC-rich-EMCV-IRES-Gluc1 (P1, No AS) IVT RNA
6: AU-rich-EMCV-IRES-Gluc1 (P1, No AS) IVT RNA
7: 2 sites-EMCV-IRES-Gluc1 (P1, No AS) IVT RNA
8: No complementary-EMCV-IRES-Gluc1 (P1, No AS) IVT RNA
 250 ng IVT RNAs/well

FIG. 18




FIG. 19



FIG. 20A




FIG. 20B